MedTrace Logo

A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults

NCT05184062 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 272

Last updated 2024-11-21

Study results available
· View outcomes & findings →

Summary

To evaluate the safety and tolerability of a single dose of 600 mg AZD7442 administered IV (intravenous) to Chinese adults (including those with stable medical conditions).

Conditions

  • Coronavirus Disease 2019 (COVID-19)

Interventions

DRUG

600 mg AZD7442 IV

Participants will be randomized to receive co-administration of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by a single IV infusion.

DRUG

600mg placebo IV

Participants will be randomized to receive co-administration of 600mg placebo by a single IV infusion.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-03
Primary Completion
2022-08-15
Completion
2023-05-06

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05184062 on ClinicalTrials.gov